Notice2023-01801
National Center for Health Statistics (NCHS), ICD-10 Coordination and Maintenance (C&M) Committee Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 30, 2023
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Abstract
The CDC, National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&M) Committee. This meeting is open to the public, limited only by the number of audio lines available. Online registration is required.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 19 (Monday, January 30, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 19 (Monday, January 30, 2023)]
[Notices]
[Pages 5882-5883]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-01801]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for Health Statistics (NCHS), ICD-10 Coordination
and Maintenance (C&M) Committee Meeting
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The CDC, National Center for Health Statistics (NCHS),
Classifications and Public Health Data Standards Staff, announces the
following meeting of the ICD-10 Coordination and Maintenance (C&M)
Committee. This meeting is open to the public, limited only by the
number of audio lines available. Online registration is required.
DATES: The meeting will be held on March 7, 2023, from 9 a.m. to 5
p.m., EST, and March 8, 2023, from 9 a.m. to 5 p.m., EST.
ADDRESSES: This is a virtual meeting. Register in advance at <a href="https://cms.zoomgov.com/webinar/register/WN__piUmNYaRjmkcYczb3ePIQ">https://cms.zoomgov.com/webinar/register/WN__piUmNYaRjmkcYczb3ePIQ</a>. After
registering, you will receive a confirmation email containing
information about joining the meeting. Further information will be
provided on each of the respective web pages when it becomes available.
For the Centers for Disease Control and Prevention, National Center for
Health Statistics: <a href="https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm">https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm</a>. For the Centers for Medicare & Medicaid
Services, Department of Health and Human Services: <a href="https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials">https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials</a>.
FOR FURTHER INFORMATION CONTACT: Traci Ramirez, Medical Systems
Specialist, National Center for Health Statistics, CDC, 3311 Toledo
Road, Hyattsville, Maryland 20782-2064; Telephone: (301) 458-4454;
Email: <a href="/cdn-cgi/l/email-protection#bfebedded2d6cddac5ffdcdbdc91d8d0c9"><span class="__cf_email__" data-cfemail="25717744484c57405f654641460b424a53">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Purpose: The ICD-10 Coordination and Maintenance (C&M) Committee is
a public forum for the presentation of proposed modifications to the
International Classification of Diseases, Tenth Revision, Clinical
Modification (CM) and ICD-10 Procedure Coding System (PCS).
Matters To Be Considered: The tentative agenda will include
discussions on the ICD-10-CM and ICD-10-PCS topics listed below. Agenda
items are subject to change as priorities dictate. Please refer to the
posted agenda for updates one month prior to the meeting.
ICD-10-PCS Topics
1. Administration of Elranatamab *
2. Administration of Epcoritamab *
3. Administration of Glofitamab *
4. Administration of Pafolacianine *
5. Administration of Posoleucel **
6. Administration of Quizartinib *
7. Administration of Rezafungin *
8. Administration of SER-109 *
9. Administration of Sulbactam-Durlobactam *
10. Implantation of Bioprosthetic Femoral Venous Valves
11. Rapid Antimicrobial Susceptibility Testing of Blood Cultures *
12. Dual-Chamber Leadless Cardiac Pacemaker *
13. Percutaneous Femoral-Popliteal Artery Bypass *
14. Insertion of Lengthening Device for Esophageal Atresia
15. Implantation of Extraluminal Saphenous Vein Graft Support Device
During Coronary Artery Bypass Graft (CABG) *
16. Short-term External Heart Assist with Graft
17. Ultrasound Ablation of Renal Sympathetic Nerves *
18. Computer-aided Detection of Heart Failure in Echocardiography *
19. Percutaneous Mechanical Circulatory Support
20. Monitoring of Intracranial Electrical Activity for Status
Epilepticus *
21. Monitoring of Intracranial Electrical Activity for Delirium *
22. Rapid Antimicrobial Susceptibility Testing System for Blood and
Body Fluid Cultures *
23. Percutaneous Hepatic Perfusion with Administration of Melphalan
Hydrochloride **
24. Insertion of Muscle Compartment Pressure Monitor *
25. Insertion of Tibial Extension Implant During Total Knee
Arthroplasty *
26. Talar Replacement of Ankle *
27. Ankle Fusion with Truss Implant *
[[Page 5883]]
28. Computer-aided Triage and Notification for Measurement of
Intracranial Vessel Flow *
29. Extravascular Implantable Defibrillator Leads
* Requestor has submitted a new technology add-on payment (NTAP)
application for FY 2024.
** Requestor intends to submit an NTAP application for FY 2025
consideration.
Presentations for procedure code requests are conducted by both the
requestor and the Centers for Medicare & Medicaid Services (CMS) during
the C&M Committee meeting. Discussion from the requestor generally
focuses on the clinical issues for the procedure or technology,
followed by the proposed coding options from a CMS analyst. Topics
presented may also include requests for new procedure codes that relate
to a new technology add-on payment (NTAP) policy request.
CMS has modified the approach for presenting the new NTAP-related
ICD-10-PCS procedure code requests that involve the administration of a
therapeutic agent. For the March 7-8, 2023, ICD-10 C&M Committee
meeting, consistent with the requirements of section 1886(d)(5)(K)(iii)
of the Social Security Act, applicants submitted requests to create a
unique procedure code to describe the administration of a therapeutic
agent, such as the option to create a new code in Section X within the
ICD-10-PCS procedure code classification. CMS will initially display
only those meeting materials associated with the NTAP-related ICD-10-
PCS procedure code requests that involve the administration of a
therapeutic agent on the CMS website in February 2023 at: <a href="https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials">https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials</a>.
The nine NTAP-related ICD-10-PCS procedure code requests that
involve the administration of a therapeutic agent are:
1. Administration of Elranatamab *
2. Administration of Epcoritamab *
3. Administration of Glofitamab *
4. Administration of Pafolacianine *
5. Administration of Posoleucel **
6. Administration of Quizartinib *
7. Administration of Rezafungin *
8. Administration of SER-109 *
9. Administration of Sulbactam-Durlobactam *
These topics will not be presented during the March 7-8, 2023,
meeting. CMS will solicit public comments regarding any clinical
questions or coding options included for these nine procedure code
topics in advance of the meeting continuing through the end of the
respective public comment periods. Members of the public should send
any questions or comments to the CMS mailbox at:
<a href="/cdn-cgi/l/email-protection#460f0502163429252322333423052922231423373323353206252b35682e2e3568212930"><span class="__cf_email__" data-cfemail="ade4eee9fddfc2cec8c9d8dfc8eec2c9c8ffc8dcd8c8ded9edcec0de83c5c5de83cac2db">[email protected]</span></a>.
CMS intends to post a question-and-answer document in advance of
the meeting to address any clinical or coding questions that members of
the public may have submitted. Following the conclusion of the meeting,
CMS will post an updated question-and-answer document to address any
additional clinical or coding questions that members of the public may
have submitted during the meeting that CMS was not able to address or
that were submitted after the meeting.
The NTAP-related ICD-10-PCS procedure code requests that do not
involve the administration of a therapeutic agent and all non-NTAP-
related procedure code requests will continue to be presented during
the virtual meeting on March 7, 2023, consistent with the standard
meeting process.
CMS will make all meeting materials and related documents available
at: <a href="https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials">https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials</a>. Any inquiries related to the procedure code topics scheduled
for the March 7-8, 2023, ICD-10 C&M Committee meeting that are under
consideration for October 1, 2023, implementation should be sent to the
CMS mailbox at: <a href="/cdn-cgi/l/email-protection#8ac3c9cedaf8e5e9efeefff8efc9e5eeefd8effbffeff9fecae9e7f9a4e2e2f9a4ede5fc"><span class="__cf_email__" data-cfemail="a4ede7e0f4d6cbc7c1c0d1d6c1e7cbc0c1f6c1d5d1c1d7d0e4c7c9d78accccd78ac3cbd2">[email protected]</span></a>.
ICD-10-CM Topics
1. Anal Fistula
2. Bicuspid Aortic Valve
3. Epileptic Seizures Related to External Causes, Intractable
4. Eating Disorders
5. Flank Anatomical Specificity
6. Gulf War Illness
7. Lymphoma in Remission
8. Nonionizing Radiation Sensitivity and Toxicity (NIRST)
9. Personal History of Colonic Polyps
10. Sepsis Aftercare
11. Addenda
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-01801 Filed 1-27-23; 8:45 am]
BILLING CODE 4163-18-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 30, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.